English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/164109
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

RGD cadherins and α2β1 integrin in cancer metastasis: a dangerous liaison

AutorCasal, J. Ignacio ; Bartolomé, Rubén Álvaro
Palabras claveCDH6
Cadherin 17
RGD motif
Therapeutic antibodies
Type IV collagen
α2β1 integrin
Fecha de publicación16-abr-2018
CitaciónBiochim Biophys Acta S0304-419X(18)30055-6 (2018)
ResumenWe propose a new cadherin family classification comprising epithelial cadherins (cadherin 17 [CDH17], cadherin 16, VE-cadherin, cadherin 6 and cadherin 20) containing RGD motifs within their sequences. Expression of some RGD cadherins is associated with aggressive forms of cancer during the late stages of metastasis, and CDH17 and VE-cadherin have emerged as critical actors in cancer metastasis. After binding to α2β1 integrin, these cadherins promote integrin β1 activation, and thereby cell adhesion, invasion and proliferation, in liver and lung metastasis. Activation of α2β1 integrin provokes an affinity increase for type IV collagen, a major component of the basement membrane and a critical partner for cell anchoring in liver and other metastatic organs. Activation of α2β1 integrin by RGD motifs breaks an old paradigm of integrin classification and supports an important role of this integrin in cancer metastasis. Recently, synthetic peptides containing the RGD motif of CDH17 elicited highly specific and selective antibodies that block the ability of CDH17 RGD to activate α2β1 integrin. These monoclonal antibodies inhibit metastatic colonization in orthotopic mouse models of liver and lung metastasis for colorectal cancer and melanoma, respectively. Hopefully, blocking the cadherin RGD ligand capacity will give us control over the integrin activity in solid tumors metastasis, paving the way for development of new agents of cancer treatment.
Descripción47 p.-3 fig.-1 tab.
Versión del editorhttp://dx.doi.org/10.1016/j.bbcan.2018.04.005
Aparece en las colecciones: (CIB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
BBA Reviews on Cancer_2018.pdf Embargado hasta 16 de abril de 2019Postprint7,65 MBAdobe PDFVista previa
Visualizar/Abrir     Petición de una copia
Mostrar el registro completo

Artículos relacionados:

NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.